NEW YORK, May 22, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of PCM Inc. ("PCM") (NASDAQ:PCMI) between June 17, 2015 and May 2, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information go to:
http://www.zlk.com/pslra-sb/pcm-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and failed to disclose that: (1) En Pointe Technologies, Inc.'s financial statements that PCM filed with the SEC materially overstated the profitability of the business; and (2) consequently, PCM's public statements were materially false and misleading at all relevant times. In April 2015, PCM acquired En Pointe Technologies, Inc. and publicly filed En Pointe's financial statements. On May 2, 2017, an article published on Seeking Alpha exposed that PCM has filed a lawsuit counterclaim alleging that En Pointe's net income was overstated and that "Had PCM known the truth about En Pointe's finances, it would not have entered into the purchase agreement" for En Pointe.
If you suffered a loss in PCM you have until July 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Anta Sports Expands Global Footprint With Strategic Puma Stake
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



